Trump says envoy Witkoff had productive meeting with Putin
DSS, Inc. (NYSE:DSS) announced the dismissal of Grassi & Co., CPAs, P.C. as its independent registered public accounting firm, effective June 27, 2025. The company’s board of directors approved the decision to replace Grassi & Co., which had served as DSS’s auditor since July 1, 2022.
According to a statement released in a press release and filed with the Securities and Exchange Commission, there were no disagreements between DSS and Grassi & Co. on any matters related to accounting principles, financial statement disclosures, or auditing procedures during the firm’s tenure. The filing states that any issues, if present, would have been referenced in Grassi & Co.’s reports on the company’s financial statements.
On the same day, DSS appointed HTL International, LLC as its new independent registered public accounting firm. HTL International will be responsible for auditing the company’s consolidated financial statements, including statements of operations, changes in stockholders’ deficit, and cash flows, along with related notes.
The company noted that during the two most recent fiscal years and through the date of engagement, DSS had not consulted with HTL International regarding the application of accounting principles to specific transactions, the type of audit opinion that might be rendered, or any matters that would constitute a disagreement or reportable event as defined under SEC regulations.
This information is based on a press release statement and the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, DSS, Inc. announced that its subsidiary, Impact BioMedical, has entered into a definitive merger agreement with Dr. Ashleys Limited, a global pharmaceutical company. This reverse merger will result in the creation of a new combined entity, which will trade on the NYSE American under the name Dr. Ashleys Limited. As part of the agreement, shares of Impact BioMedical, including those held by DSS, will be converted into ordinary shares of the new public company, representing 4.80% of the combined entity’s total outstanding shares at closing. The merger involves several preliminary steps, such as the conversion of Impact’s Series A Preferred Stock and the exercise of DSS’s debt-to-equity rights. The transaction has been unanimously approved by the boards of both companies and awaits Impact’s shareholder approval, regulatory approvals, and other customary closing conditions. Dr. Ashleys’ management team will operate the newly formed public company, with a new Board of Directors to be assembled by Dr. Ashleys. This merger is part of DSS’s broader strategy to structure its subsidiaries as standalone public entities through various strategic transactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.